[Federal Register Volume 79, Number 19 (Wednesday, January 29, 2014)]
[Notices]
[Pages 4730-4743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-01635]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of the patent applications.
Novel Targets To Prevent Borrelia burgdorferi Infection and Lyme
Disease
Description of Technology: B. burgdorferi-infected ticks can cause
Lyme disease in mammalian hosts. This technology relates to the use of
B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease
vaccine candidates. In vivo animal studies demonstrate these outer
surface proteins inhibit tick-to-host B. burgdorferi transmission.
Presently, there is no vaccine approved for Lyme disease.
This technology may also be used for creation of antibodies
directed against B. burgdorferi. Thus, this innovation may prevent B.
burgdorferi infection by passive immunity and provide new diagnostic
tools, which will allow early intervention.
Potential Commercial Applications:
B. burgdorferi/Lyme disease vaccine development
B. burgdorferi diagnostics
Prevention of B. burgdorferi infection by passive immunity
Zoonotic/tick-borne disease surveillance
Public health vaccination programs against Lyme disease
Competitive Advantages: Currently no approved Lyme disease vaccines
Development Stage:
Early-stage
In vitro data available
In vivo data available (animal)
Inventor: Robert D. Gilmore (CDC)
Publication: Patton TG, et al. Borrelia burgdorferi bba66 gene
inactivation results in attenuated mouse infection by tick
transmission. Infect Immun. 2013 Jul;81(7):2488-98. [PMID 23630963]
Intellectual Property: HHS Reference No. E-573-2013/0--US
Provisional Application No 61/814,741 filed 22 Apr 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Real-Time RT-PCR Assay for Detection and Quantification of Hepatitis D
Virus Infection
Description of Technology: CDC scientists have developed a one-step
TaqMan quantitative/real-time reverse transcription-polymerase chain
reaction (qRT-PCR) assay for detecting hepatitis D virus (HDV) RNA.
Additionally, a quantifiable synthetic RNA control to determine viral
load has been created.
HDV is an operatively defective virus that requires hepatitis B
virus (HBV) surface antigen (HBsAg) for its assembly. Compared to
individuals infected with HBV alone, individuals infected with both HDV
and HBV
[[Page 4731]]
viruses present with more severe hepatitis, progress to liver disease
more quickly, and have a higher mortality rate. Currently, there are no
regulated tests available for detection and quantification of HDV RNA.
This assay directly addresses this unmet need and has been validated
with clinical samples of HDV genotypes 1 and 3. It has the potential to
detect all eight HDV genotypes.
Potential Commercial Applications:
Development of a commercial nucleic acid assay for
diagnosis of current hepatitis D virus (HDV) infection
Public health and vaccination programs
Testing of individuals infected with hepatitis B and/or
liver disease
Competitive Advantages:
Rapid, accurate, inexpensive and stable
Unique RNA transcript for this assay can be successfully
used as a quantitative standard
Current anti-HDV antibody assay identifies individuals
exposed to HDV, but cannot identify current infection
Easily adapted for inclusion in a hepatitis testing kit,
especially when paired with a hepatitis B diagnostic
Development Stage:
Pre-clinical
In vitro data available
Inventors: Maja Kodani, Tonya Mixson-Hayden, Saleem Kamili (all of
CDC)
Publication: Kodani M, et al. One-step real-time PCR assay for
detection and quantitation of hepatitis D virus RNA. J Virol Methods.
2013 Nov;193(2):531-5. [PMID 23896020]
Intellectual Property: HHS Reference No. E-510-2013/0--US
Provisional Application No. 61/792,293 filed 15 Mar 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Reduced Virulence Crimean-Congo Hemorrhagic Fever Virus for Vaccine
Development
Description of Technology: This invention relates to a genetically
modified hemorrhagic fever virus that can be used as an effective live
vaccine agent. Hemorrhagic fever evades the human immune response using
the viral ovarian tumor domain (vOTU) protease, which inhibits critical
host-immunity functions. The present genetically modified virus has a
vOTU protease with decreased ability to remove ubiquitin (Ub) and ISG15
tags from proteins in cells it infects. Thus, the virulence is reduced,
creating an immunogenic and non-pathogenic virus for use as a live
vaccine against Crimean-Congo hemorrhagic fever (CCHF) virus. Unlike
strains with complete ablation of the vOTU protease, the present
modified virus retains enough activity for replication in a human cell
line, making vaccine production possible. This technology may be used
to create vaccines or therapeutics for other nairoviruses, including
the Dugbe, Hazara, and Nairobi sheep disease viruses.
Potential Commercial Applications: Development of vaccines or
therapeutics for CCHF virus and other nairoviruses, including Dugbe,
Hazara and Nairobi sheep disease viruses
Competitive Advantages:
Increased safety for CCHF laboratory research (Biosafety
Level 2)
Use of human cell lines allows large-scale manufacturing
of vaccines
vOTU domain-disruption may be used to develop vaccines for
all nairovirus viruses affecting humans and/or livestock
Development Stage:
Pre-clinical
In vitro data available
Inventors: Eric Bergeron (CDC), Stuart T. Nichol (CDC), et al.
Publications:
1. Bergeron E, et al. Crimean-Congo hemorrhagic fever virus-encoded
ovarian tumor protease activity is dispensable for virus RNA polymerase
function. J Virol. 2010 Jan;84(1):216-26. [PMID 19864393]
2. Capodagli GC, et al. Structural analysis of a viral ovarian
tumor domain protease from the Crimean-Congo hemorrhagic fever virus in
complex with covalently bonded ubiquitin. J Virol. 2011 Apr;85(7):3621-
30. [PMID 21228232]
Intellectual Property: HHS Reference No. E-486-2013/0--
US Provisional Application No. 61/683,132 filed 14 Aug
2012
US Patent Application No. 13/829,105 filed 14 Mar 2013
PCT Application No. PCT/US13/54760 filed 13 Aug 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Human Influenza Virus Real-Time RT-PCR Detection and Characterization
Panel
Description of Technology: This invention relates to methods of
rapidly detecting influenza, including differentiating between type and
subtype. Unlike culture and serological tests requiring 5 to 14 days
for completion, CDC researchers developed a rapid, accurate assay,
which is easily adapted to kit form. This assay also requires less
labor input than immunoassays. These methods can be used to quickly
identify a broad variety of influenza types and subtypes, including
viruses that may be involved in pandemics (such as H5N1, for example).
Potential Commercial Applications:
Influenza diagnostic using clinical specimens
High-throughput screenings
Influenza surveillance programs
Competitive Advantages:
Already FDA approved
Especially useful for H5N1 screening
Sensitive detection
Specific discrimination of influenza subtypes
Easily formatted as kit or array
Faster than culturing and serological identification
methods
Less laborious and more objective than immunoassays
Development Stage: In vitro data available
Inventors: Stephen Lindstrom, Alexander I. Klimov, Nancy J. Cox,
Lamorris Loftin (all of CDC)
Publication: Jernigan DB, et al. Detecting 2009 pandemic influenza
A (H1N1) virus infection: availability of diagnostic testing led to
rapid pandemic response. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S36-43.
[PMID 21342897]
Intellectual Property: HHS Reference No. E-331-2013/0--
PCT Application No. PCT/US2007/003646 filed 12 Feb 2007,
which published as WO 2007/095155 on 23 Aug 2007
US Patent No. 8,241,853 issued 14 Aug 2012
US Patent No. 8,568,981 issued 29 Oct 2013
US Patent Application No. 14/056,810 filed 17 Oct 2013
Various international patent applications pending or
issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Peptide Vaccines Against Group A Streptococci
Description of Technology: This invention relates to synthetic
immunoreactive peptides, which are portions of the M proteins of the
most prevalent Group A Streptococcus (GAS) serotypes in the United
States. These peptides may be useful in development of a flexible,
multivalent GAS vaccine. They can be recognized by M type-specific
antibodies and are capable of eliciting functional opsonic antibodies.
Additionally, the peptides or isolated antibodies raised in response to
the peptides may be useful for GAS diagnostics.
[[Page 4732]]
Potential Commercial Applications:
Group A streptococci (GAS) vaccine
GAS therapeutics and diagnostics
Lab tools for exploring GAS
Competitive Advantages:
Easily adaptable to kit form
Multivalent vaccine that can be tailored for protection
against specific GAS serotypes affecting a particular population
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Bernard W. Beall, George M. Carlone, Jacquelyn S.
Sampson, Edwin W. Ades (all of CDC)
Publication: Bruner M, et al. Evaluation of synthetic, M type-
specific peptides as antigens in a multivalent group A streptococcal
vaccine. Vaccine. 2003 Jun 20;21(21-22):2698-703. [PMID 12798606]
Intellectual Property: HHS Reference No. E-330-2013/0--
US Patent No. 7,407,664 issued 05 Aug 2008
US Patent No. 7,883,710 issued 08 Feb 2011
US Patent No. 8,420,107 issued 16 Apr 2013
US Patent Application No. 13/846,166 filed 18 Mar 2013
Various international patent applications pending or
issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Method of Enhancing Opsonophagocytosis
Description of Technology: This invention aims to bolster the human
body's own mechanisms to fight infection by enhancing an innate immune
response, opsonophagocytosis. The specific 24 amino acid sequence (P4)
acts as a polymorphonuclear cell activator. P4 can be administered in
vivo along with a disease's specific antibody to enhance systemic
bacterial clearance, thus leading to prolonged survival. This
technology enhances the body's response to infections such as S.
pneumoniae and S. aureus.
Potential Commercial Applications:
Opsonic therapy
Passive immunization
Enhancement of pathogen clearing
Synergistic use with other therapies
Competitive Advantages:
Multiple in vivo studies indicate significant improvements
in recipient outcomes
Highly adaptable and can be combined with a number of
alternate therapies
Enhances opsonophagocytosis to achieve therapeutically
effective results
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Edwin W. Ades, et al. (CDC)
Publications:
1. Melnick N, et al. Evaluation of a novel therapeutic approach to
treating severe pneumococcal infection using a mouse model. Clin
Vaccine Immunol. 2009 Jun;16(6):806-10. [PMID 19386795]
2. Weeks JN, et al. Immunotherapy with a combination of intravenous
immune globulin and p4 peptide rescues mice from postinfluenza
pneumococcal pneumonia. Antimicrob Agents Chemother. 2011
May;55(5):2276-81. [PMID 21383090]
3. Bangert M, et al. P4-mediated antibody therapy in an acute model
of invasive pneumococcal disease. J Infect Dis. 2012 May 1;205(9):1399-
407. [PMID 22457294]
Intellectual Property: HHS Reference No. E-329-2013/0--
PCT Application No. PCT/US2009/052384 filed 31 Jul 2009,
which published as WO 2010/14888 on 04 Feb 2010
US Patent No. 8,431,134 issued 30 Apr 2013
US Patent Application No. 13/851,508 filed 27 Mar 2013
Various international applications pending or issued
Related Technologies: HHS Reference No. E-338-2013/0--
PCT Application No. PCT/US2005/027290 filed 29 Jul 2005,
which published as WO 2006/127020 on 30 Nov 2006
US Patent No. 7,919,104 issued 05 Apr 2011
Australia Patent No. 2005332058 issued 15 Mar 2012
Various international patent applications pending or
issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Collaborative Research Opportunity: The Centers for Disease Control
and Prevention (CDC) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Methods and Tools for Enhancing
Opsonophagocytosis in Response to a Pathogen. For collaboration
opportunities, please contact Suzanne Shope at [email protected] or 770-
488-8613.
Novel Live-Attenuated Rabies Vaccine
Description of Technology: The critical feature of this technology
is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA
sequence. With the availability of the entire rabies genome, a
recombinant vaccine can be developed using reverse genetics. Using this
technology, CDC researchers have developed a recombinant, live-
attenuated vaccine shown to confer protection against lethal doses of
live, street-rabies virus in multiple survival studies. This vaccine
offers better protection than traditional inactivated vaccinations, as
demonstrated in co-infection studies. Further, a single intramuscular
vaccination with the CDC's attenuated-virus was sufficient for survival
of 100% of hamsters and mice following lethal challenge.
Potential Commercial Applications:
Rabies vaccine design and development
Immunogenic compositions for both prevention and treatment
of rabies virus
Rabies virus research
Competitive Advantages:
Live attenuated vaccine shows greater efficacy than older
inactivated vaccine
100% animal survival conferred by a single inoculation
before lethal challenge
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Charles E. Rupprecht and Xianfu Wu (CDC)
Publications:
1. Wu X, et al. Are all lyssavirus genes equal for phylogenetic
analyses? Virus Res. 2007 Nov;129(2):91-103. [PMID 17681631]
2. Bankovskiy D, et al. Immunogenicity of the ERA G 333 rabies
virus strain in foxes and raccoon dogs. Dev Biol (Basel). 2008;131:461-
6. [PMID 18634508]
3. Wu X, Rupprecht CE. Glycoprotein gene relocation in rabies
virus. Virus Res. 2008 Jan;131(1):95-9. [PMID 17850911]
4. Franka R, et al. Rabies virus pathogenesis in relationship to
intervention with inactivated and attenuated rabies vaccines. Vaccine.
2009 Nov 27;27(51):7149-55. [PMID 19925945]
5. Wu X, et al. Live attenuated rabies virus co-infected with
street rabies virus protects animals against rabies. Vaccine. 2011 Jun
6;29(25):4195-201. [PMID 21514343]
Intellectual Property: HHS Reference No. E-326-2013/0--
PCT Application No. PCT/US2006/040134 filed 13 Oct 2006,
which published as WO 2007/047459 on 26 Apr 2007
US Patent No. 7,863,041 issued 04 Jan 2011
[[Page 4733]]
US Patent Application No. 12/956,949 filed 30 Nov 2010
Various international patent applications pending or
issued
Related Technologies: HHS Reference No. E-256-2013/0--
PCT Application No. PCT/US2011/041579 filed 23 June 2011,
which published as WO 2011/163446 on 29 Dec 2011
US Patent Application No. 13/806,622 filed 21 Dec 2012
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Intranasal Nebulizer With Disposable Drug Cartridge for Improved
Delivery of Vaccines and Therapeutics
Description of Technology: Intranasal delivery is a simple,
inexpensive and needle-free route for administration of vaccines and
therapeutics. This intranasal delivery technology, developed with
Creare, Inc., includes low-cost, disposable drug cartridges (DDCs) that
mate with a durable hand-held device. The rechargeable-battery-powered
device transmits ultrasonic energy to the DDC to aerosolize the drug
and is capable of performing for eight hours at 120 vaccinations per
hour. Potential applications for this platform technology include
intranasal vaccination (e.g. seasonal or pandemic influenza vaccines)
and intranasal delivery of locally active (e.g. antihistamines,
steroids) or systemically active (e.g. pain medications, sedatives)
pharmaceuticals.
The DDCs themselves offer two unique benefits. First, all
components that contact the active agent or the patient may be easily
disposed of, which reduces the risk of patient cross-contamination and
minimizes cleaning and maintenance requirements of the hand-held
device. Second, DDCs provide a low-cost and simple method to package
and distribute individual doses.
This technology also allows for significant dose-sparing.
Preliminary studies have shown robust immune responses when this
technology is used to delivery significantly reduced doses of Live
Attenuated Influenza Vaccine in animal models. The intranasal nebulizer
produces droplets sized for optimum depositioning in the nasal airway.
The small nebulizer droplets essentially ``spray paint'' the internal
nasal airway, resulting in an increased tissue surface coverage that
may enable a significant dose reduction. In contrast, currently
available nasal delivery devices, such as nasal sprays and droppers, do
not provide efficient intranasal delivery in humans because the large
droplets they generate fail to coat a significant portion of the nasal
airway. Large droplets also tend to drip out of the nose or down the
throat, which can be unpleasant for the patient in addition to wasting
a sizable portion of the active agent.
Potential Commercial Applications:
Intranasal delivery of vaccines and therapeutics
Childhood vaccination programs, mass immunization
campaigns, or response to epidemics
Competitive Advantages:
Safe, needle-less delivery
No patient-to-patient contamination
Long-life, rechargeable battery
Consistent delivery and dose-sparing
Nasal delivery of live-attenuated vaccines may be more
effective than traditional injected vaccines
Cost-effective
Reduces biohazard waste
May be administered by personnel with minimal medical
training
Easy means of delivery to children with fear of needles
Development Stage:
Prototype
In vitro data available
In vivo data available (animal)
Inventors: Mark J. Papania (CDC), et al.
Publication: Smith JH, et al. Nebulized live-attenuated influenza
vaccine provides protection in ferrets at a reduced dose. Vaccine. 2012
Apr 19;30(19):3026-33. [PMID 22075083]
Intellectual Property:
HHS Reference No. E-323-2013/0--
--PCT Application No. PCT/US2002/007973 filed 13 Mar 2002, which
published as WO 2002/074372 on 26 Sep 2002
--US Patent No. 7,225,807 issued 05 Jun 2007
--US Patent No. 8,544,462 issued 01 Oct 2013
--Various international issued patents
HHS Reference No. E-324-2013/0--
--PCT Application No. PCT/US2005/011086 filed 01 Apr 2005, which
published as WO 2006/006963 on 19 Jan 2006
--US Patent No. 7,954,486 issued 07 Jun 2011
--US Patent Application No. 13/099,261 filed 02 May 2011
--Various international issued patents
HHS Reference No. E-308-2013/0--
--PCT Application No. PCT/US2011/039020 filed on 03 Jun 2011, which
published as WO 2011/153406 on 08 Dec 2011
--US Patent Application No. 13/701,992 filed 04 Dec 2012
--Various international pending patents
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Multiplexed Immunoassay for Rapid Serological Diagnosis of a Specific
Viral Infection in Clinical Samples
Description of Technology: CDC researchers have developed a
multiplexed diagnostic assay for sensitive detection and distinction
between viral group members based on the presence/absence of infection-
generated antibodies within a clinical serum sample. For example, this
assay can be used for rapid discrimination of a clinical unknown as
specifically a West Nile or St. Louis encephalitis viral infection.
This is particularly beneficial as these two viruses are typically
difficult to distinguish by standard serological assays.
This new technique uses microsphere/microbead-based flow-analysis
as a platform. Because of a basis in a pre-existing technology, the
technique can be easily incorporated into current state and health
department diagnostic testing protocols. The method is particularly
unique because the assay-generated data can be standardized and then
classified via discriminant analysis to determine the presence or
absence of antibodies of interest within the clinical sample tested.
Furthermore, along with allowances for single-result generation,
data manipulation and classification algorithms allow for assay output
comparisons to the original large data set references used in
development. In this way, results from different laboratories can now
be directly compared to one another, provided that the same controls
are used.
Potential Commercial Applications:
Clinical diagnostics for specific identification and
discrimination of viral infections
Research tool for evaluation of vaccine candidates
Assay standardization and quality control
Public health and viral outbreak surveillance programs
Competitive Advantages:
Increased efficiency compared to single-antibody
diagnostic approaches
Easily implemented and integrated into present protocols
and techniques, as this technology is based on current, widely used
flow-analysis platforms
Can be formatted as customizable kits for detection of
viral group antibodies
Rapid and precise
Ideal for high-throughput analyses
[[Page 4734]]
Development Stage: In vitro data available
Inventors: Alison J. Basile and Bradley J. Biggerstaff (CDC)
Publications:
1. Basile AJ, et al. Removal of species constraints in antibody
detection. Clin Vaccine Immunol. 2010 Jan;17(1):56-61. [PMID 19923570]
2. Basile AJ, et al. Multiplex microsphere immunoassays for the
detection of IgM and IgG to arboviral diseases. PLoS One. 2013 Sep
25;8(9):e75670. [PMID 24086608]
Intellectual Property: HHS Reference No. E-302-2013/0--
US Patent No. 7,933,721 issued 26 Apr 2011
US Patent No. 8,433,523 issued 30 Apr 2013
Various international patent applications pending or
issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Real-Time PCR Multiplex Assay for Detection of Bacterial Respiratory
Pathogens in Clinical Specimens
Description of Technology: CDC researchers have developed a single-
tube, real-time PCR assay for the simultaneous detection of three
bacterial respiratory pathogens (Mycoplasma pneumoniae, Chlamydiophila
pneumoniae and Legionella spp.). The assay has an internal control
testing for presence of human DNA. This four-plex real-time PCR assay
could potentially become a routine screening test for patients with
respiratory illness. Ninety four clinical specimens (in a 96-well
format) can be tested at once. This assay is non-invasive, rapid and
cost-effective. It has the potential for point-of-care applications in
population-based pneumonia surveillance.
Potential Commercial Applications:
Population-based pneumonia surveillance
Development of broadly-capable respiratory clinical
diagnostics
Competitive Advantages:
Sensitive and specific
High-throughput friendly
Rapid and cost-effective compared to screening for
individual respiratory pathogens
Easily developed for use in diagnostic kits
Development Stage:
Pre-clinical
In vitro data available
Inventors: Jonas Winchell, Agnes Warner, Kathleen Thurman (all of
CDC)
Publication: Thurman KA, et al. Detection of Mycoplasma pneumoniae,
Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a
single-tube multiplex real-time PCR assay. Diagn Microbiol Infect Dis.
2011 May;70(1):1-9. [PMID 21397428]
Intellectual Property: HHS Reference No. E-300-2013/0--
PCT Application No. PCT/US2011/032749 filed 15 Apr 2011,
which published as WO 2011/133433 on 27 Oct 2011
US Patent Application No. 13/641,444 filed 28 Nov 2012
Various international patent applications pending or
deferred
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Novel Recombinant Rabies Vaccine Also Capable of Immunocontraception
Description of Technology: This invention relates to a recombinant,
attenuated rabies vaccine that is also capable of inhibiting
reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies
vaccine backbone, combined with a reproductive-specific protein, such
as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-
pellucida-glycoprotein-3 (ZP3) receptor, allows reduction in both
rabies transmission and uncontrolled reproduction in stray animals. The
ERA rabies vaccine backbone has previously shown strong efficacy in
animal studies. This vaccine may be delivered via injection or orally,
including in an animal's food.
Potential Commercial Applications:
Development of rabies and immunocontraceptive vaccines
Immunogenic compositions for both prevention and treatment
of rabies virus
Animal welfare initiatives and rabies vaccination programs
Competitive Advantages:
Live, attenuated rabies vaccines show greater efficacy
than older, inactivated rabies vaccine in prior animal studies
Potential for oral delivery, enabling vaccination of feral
and difficult-to-reach animal populations
Novel approach to simultaneously addressing rabies
transmission and uncontrolled wild animal reproduction
Development Stage:
Pre-clinical
In vitro data available
In vivo data available (animal)
Inventors: Xianfu Wu and Charles E. Rupprecht (CDC)
Publication: Wu X, et al. Development of combined vaccines for
rabies and immunocontraception. Vaccine. 2009 Nov 27;27(51):7202-9.
[PMID 19925954]
Intellectual Property: HHS Reference No. E-298-2013/0--
PCT Application No. PCT/US2009/054502 filed 20 Aug 2009,
which published as WO 2010/033337 on 25 Mar 2010
US Patent Application No. 13/062,680 filed 07 Mar 2011
Various international patent applications pending or
deferred
Related Technologies:
HHS Reference No. E-256-2013/0--
--PCT Application No. PCT/US2011/041579 filed 23 June 2011, which
published as WO 2011/163446 on 20 Dec 2011
--US Patent Application No. 13/806,622 filed 21 Dec 2012
HHS Reference No. E-326-2013/0--
--PCT Application No. PCT/US2006/040134 filed 13 Oct 2006, which
published as WO 2007/047459 on 26 Apr 2007
--US Patent No. 7,863,041 issued 04 Jan 2011
--Various international patent applications pending or issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Diagnostic Assays Utilizing Real-Time Taqman or Seminested RT-PCR for
Parechovirus Detection and Discrimination
Description of Technology: The CDC developed a real-time reverse
transcription polymerase chain reaction (RT-PCR) Taqman assay and an
RT-semi nested PCR (RT-snPCR) assay for the detection of
parechoviruses. Similar to enteroviruses, parechoviruses are
responsible for gastrointestinal, respiratory and central nervous
system infections. All tests target conserved regions in the
5'nontranslated region (5'NTR) of the parechovirus genome and share
forward and reverse primers. The Taqman probe and RTsnPCR nested primer
target the same conserved site but vary in length. Both assays detect
all known human parechoviruses (PPeV) and Ljungan viruses (LV), unlike
other published parechovirus 5'NTR assays, which only detect a limited
number of PPeV types. Both assays are more sensitive than current
methods (culture and multiple, single-serotype nucleic acid
amplification assays) and may be used to test isolates or original
clinical specimens.
Potential Commercial Applications:
Diagnostic detection of all known species of Parechovirus
from clinical samples, including Human parechovirus and Ljungan virus
Discrimination of specific species and serotypes
Public health surveillance programs
Research tool for all lab strains and clinical isolates of
parechovirus
[[Page 4735]]
Competitive Advantages:
Detects all Parechovirus genus members with a single assay
Rapid, accurate, sensitive and specific
Cost-effective in terms or resource-input, labor and
turnaround time
Does not require culturing
Easily adaptable to kit form
Development Stage:
Early-stage
In vitro data available
Inventors: William A. Nix and M. Steven Oberste (CDC)
Intellectual Property: HHS Reference No. E-295-2013/0--
PCT Application No. PCT/US2006/016624 filed 01 May 2006,
which published as WO 2007/133189 on 22 Nov 2007
US Patent No. 8,048,630 issued 01 Nov 2011
Australian Patent No. 2006343645 issued 05 Apr 2012
Various international filings pending or issued
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected]
Collaborative Research Opportunity: The Centers for Disease Control
and Prevention (CDC) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Diagnostic Assays Utilizing Real-Time Taqman
or Seminested RT-PCR for Parechovirus Detection and Discrimination. For
collaboration opportunities, please contact Suzanne Shope at
[email protected] or 770-488-8613.
Simultaneous Detection of Non-Pneumophila Legionella Strains Using
Real-Time PCR
Description of Technology: Legionnaires' disease is caused by a
type of bacteria called Legionella. CDC scientists have developed a
real-time multiplex PCR assay for diagnosis and identification of
Legionella strains. The assay consists of five sets of primers
(targeting L. bozemanii, L. dumoffii, L. feeleii, L. longbeachae, or L.
micdadei) and corresponding probes. Each probe is labeled with a
different fluorophore which allows the detection of a particular strain
in a single tube reaction. Using this assay format, the presence of any
one of the five pathogenic non-pneumophila strains of Legionella can be
detected rapidly from clinical or environmental samples. Rapid and
sensitive identification enables initiation of appropriate antibiotic
therapy and identification of the source of bacteria so that proper
public health responses may occur.
Potential Commercial Applications: Rapid and real-time assay to
detect the presence of clinically relevant non-pneumophila Legionella
strains.
Competitive Advantages:
Currently available tests are time consuming and labor
intensive.
This assay enables rapid identification and
differentiation on clinically relevant non-pneumophila Legionella
strains.
This assay can be used as a standalone confirmatory assay
for the detection of common non-pneumophila Legionella species or as
one of the valuable assays in conjunction with other standard assays.
Inventors: Jonas M. Winchell and Alvaro J. Benitez (CDC)
Publication: Benitez AJ, Winchell JM. Clinical application of a
multiplex real-time PCR assay for simultaneous detection of Legionella
species, Legionella pneumophila, and Legionella pneumophila serogroup
1. J Clin Microbiol. 2013 Jan;51(1):348-51. [PMID 23135949]
Intellectual Property:
HHS Reference No. E-277-2013/0--PCT Application No. PCT/
US2013/030217 filed 11 March 2013, which published as WO 2013/187958 on
19 Dec 2013
HHS Reference No. E-277-2013/1--US Patent Application No.
13/895,898 filed 16 May 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Multiplex Real-Time PCR Assay for Detection of Numerous Bacterial
Pathogens
Description of Technology: In order to address a global need for
rapid, cost-effective, sensitive, and specific assays for many
pathogens, CDC scientists have developed a broad-use, multiplexed RT-
PCR assay. This comprehensive assay covers numerous pathogens that are
common causes of infection in neonates and also important to food-
safety. Specifically, this assay (and respective probes, primers, and
kits) is capable of detecting one or more of Acinetobacter baumannii,
Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii,
Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus
aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma
urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp.,
Streptococcus agalactiae, and Neisseria meningitidis in a biological
sample.
Potential Commercial Applications:
Clinical diagnostic for several pathogens
Drug-resistance surveillance
Public health monitoring
En masse food-safety screening
Competitive Advantages:
Cost-effective
Simple to implement
Rapid, accurate and objectively conclusive
Easily implemented into kit format
Ideal for high-throughput scenarios
Development Stage:
Pre-clinical
In vitro data available
Inventors: Jonas Winchell, Bernard Wolff, Maureen Diaz (all of CDC)
Publication: Diaz MH, et al. Optimization of Multiple Pathogen
Detection Using the TaqMan Array Card: Application for a Population-
Based Study of Neonatal Infection. PLoS One. 2013 Jun 21;8(6):e66183.
[PMID 23805203]
Intellectual Property: HHS Reference No. E-276-2013/0--
US Provisional Patent Application No. 61/642,091 filed 03
May 2012
PCT Application No. PCT/US13/28034 filed 27 Feb 2013,
which published as WO 2013/165537 on 07 Nov 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Methods of Detecting and Identifying Both Known and Novel Influenza
Viruses
Description of Technology: This invention describes materials and
methods of detecting novel influenza virus in a sample. As highlighted
by the recent H1N1 pandemic strain, influenza viruses are constantly
evolving and novel reassortments can quickly spread around the world.
The reagents and methods of this particular technology are capable
of detecting any type of influenza virus (such as influenza A virus,
influenza B virus, and influenza C virus) in a sample, including novel
or previously unknown influenza viruses. Such methods and compositions
are useful for diagnosing influenza virus infection in humans and
animals.
Potential Commercial Applications:
Method of rapid, accurate subtype-screening of influenza
viruses using ``pan-influenza'' RT-PCR
Diagnostic tool for clinicians, veterinarians, public
health programs, food-safety officials, researchers and forensic
scientists
Competitive Advantages:
A full-spectrum, sensitive and specific assay for
identification of influenza viruses, known and novel
Easily adaptable for commercial production
[[Page 4736]]
Development Stage:
Pre-clinical
In vitro data available
Inventors: Suxiang Tong and Shannon Rogers (CDC)
Publications:
1. Fouchier RA, et al. Characterization of a novel influenza A
virus hemagglutinin subtype (H16) obtained from black-headed gulls. J
Virol. 2005 Mar;79(5):2814-22. [PMID 15709000]
2. Fouchier RA, et al. Detection of influenza A viruses from
different species by PCR amplification of conserved sequences in the
matrix gene. J Clin Microbiol. 2000 Nov;38(11):4096-101. [PMID
11060074]
3. Tong S, et al. Sensitive and broadly reactive reverse
transcription-PCR assays to detect novel paramyxoviruses. J Clin
Microbiol. 2008 Aug;46(8):2652-8. [PMID 18579717]
Intellectual Property: HHS Reference No. E-274-2013/0--
US Provisional Application No. 61/642,098 filed 03 May
2012
PCT Application No. PCT/US2013/029600 filed 07 Mar 2013,
which published as WO 2013/165551 on 07 Nov 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected]
Collaborative Research Opportunity: The Centers for Disease Control
and Prevention (CDC) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Methods of Detecting and Identifying Both
Known and Novel Influenza Viruses. For collaboration opportunities,
please contact Suzanne Shope at [email protected] or 770-488-8613.
Nucleic Acid Amplification Technique for Rapid Diagnostic Analysis
Description of Technology: CDC researchers developed a simple
target-specific isothermal nucleic acid amplification technique, termed
Genome Exponential Amplification Reaction (GEAR). The method employs a
set of four primers (two inner and two outer). The outer primer pair
targets three specific nucleic acid sequences at a constant 60 [deg]C,
while the inner pair of primers accelerates and improves the
sensitivity of the assay.
The GEAR technique is an improvement over loop-mediated isothermal
amplification (LAMP) in three ways. First, the GEAR method uses two Tab
primers which target three genomic regions (corresponding LAMP primers
target four regions). Second, the GEAR method features complementary 5'
ends between the forward and reverse primers. Third, the GEAR method
does not require a second set of outer primers (LAMP requires two
outermost primers). Additionally, the GEAR isothermal method can be
performed in a relatively inexpensive water bath or heating block, with
detection of amplification products by fluorescence, thus making it
suitable for low resource settings.
Potential Commercial Applications:
Rapid diagnostic analysis of biological samples
Qualitative and quantitative analysis of nucleic acids
Low-cost diagnostics for malaria, tuberculosis, and other
infectious diseases
Competitive Advantages:
Rapid, portable, cost-effective
Useful in low resource settings
A ``single-tube'' assay that eliminates need for thermal
cyclers or gel electrophoresis
Unlike many other isothermal amplification approaches,
GEAR can be efficiently performed at temperatures exceeding 60 [deg]C,
increasing specificity and accuracy
Development Stage:
Pre-clinical
In vitro data available
Inventors: Jothikumar Narayanan, Prithiviraj Jothikumar, Vincent R.
Hill (all of CDC)
Publication: Prithiviraj J, et al. Rapid detection of microbial DNA
by a novel isothermal genome exponential amplification reaction (GEAR)
assay. Biochem Biophys Res Commun. 2012 Apr 20;420(4):738-42. [PMID
22450319]
Intellectual Property: HHS Reference No. E-273-2013/0--PCT
Application No. PCT/US2012/049784 filed 06 Aug 2012
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Diagnostics, Vaccines, and Delivery-Vehicles Related to Novel
Phlebovirus
Description of Technology: This CDC invention relates to primers
and probes that specifically hybridize with Heartland virus (HRTLDV), a
unique member of the genus Phlebovirus. It further relates to
polyclonal antibodies specific for HRTLDV proteins. Serological
detection assays using HRTLDV nucleic acid molecules, proteins, probes,
primers, and antibodies are provided. Importantly, the HRTLDV genome
can be engineered using reverse genetics to be attenuated, allowing
development of a vaccine for other viruses within the Phlebovirus genus
or Bunyaviridae family. Individual proteins or peptides of the HRTLDV
can also be used in other FDA-approved virus backbones to act as
vaccines. Further, since HRTLDV targets the bone marrow, disclosed
HRTLDV delivery vehicles may be used to deliver therapeutic agents to
the bone marrow.
Potential Commercial Applications:
Development of nucleic acid (RT-PCR) and serologic
diagnostic assays for phleboviruses
Phlebovirus vaccines
Novel delivery vehicles for bone marrow-originating
diseases
Research tool for phlebovirus virulence mechanisms
Vector or tick-borne illness monitoring programs for both
humans and wildlife
Competitive Advantages:
Antigens and antibodies for diagnostic use have been
developed
RT-PCR allows rapid, quantitative diagnosis
Potential use as bone marrow therapeutic delivery tools
Recombinant, pseudo-phlebovirus reporter systems have
potential for a wide range of high-throughput drug-screening and
research applications
Development Stage:
Early stage
In vitro data available
Inventors: Laura K. McMullan, Cynthia S. Goldsmith, Aubree J.
Kelly, William L. Nicholson, Stuart T. Nichol (all of CDC)
Publications:
1. McMullan LK, et al. A new phlebovirus associated with severe
febrile illness in Missouri. N Engl J Med. 2012 Aug 30;367(9):834-41.
[PMID 22931317]
2. CDC FAQs: Novel phlebovirus (Heartland virus) [http://www.cdc.gov/ncezid/dvbd/heartland/index.html ]
Intellectual Property: HHS Reference No. E-269-2013/0--
US Provisional Patent Application No. 61/614,926 filed 23
Mar 2012
PCT Application No. PCT/US2013/033541 filed 22 Mar 2013,
which published as WO 2013/142808 on 26 Sep 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
HIV-1 Genotyping Assay for Subtype Diagnosis and Global Surveillance of
Drug Resistance
Description of Technology: CDC researchers have developed a set of
RT-PCR and sequencing primers based on HIV-1 group M sequences.
Evaluation of the primers using samples collected around the world
demonstrated broad detection capacity for multiple HIV-1 group subtypes
and predominant circulating recombinant forms. Further, commercially
available HIV-1 drug resistance (HIVDR) genotyping assays
[[Page 4737]]
are expensive and have limited ability to detect non-B subtypes. This
optimized assay is broadly sensitive in genotyping HIV-1 group M viral
strains and more sensitive than TRUGENE[supreg] and ViroSeq[supreg]
assays in detecting mixed viral populations. Additionally, this assay
is useful in resource-limited settings where HIVDR surveillance is
recommended to minimize the development and transmission of HIVDR.
Potential Commercial Applications:
HIV-1 sub-typing diagnostic
Evaluation of efficacy of anti-HIV therapeutics
HIV drug resistance (HIVDR) surveillance and monitoring
Competitive Advantages:
Cost-effective
Simple to implement
Rapid, accurate and objectively conclusive
Easily implemented as a kit
Assay could be applicable to HIVDR genotyping in both ART-
naive and ART-experienced populations
Development Stage:
Pre-clinical
In vitro data available
Inventors: Nicholas Wagar, Chunfu Yang, Zhiyong Zhou, Joshua DeVos
(all of CDC)
Publications:
1. Zhou Z, et al. Optimization of a low cost and broadly sensitive
genotyping assay for HIV-1 drug resistance surveillance and monitoring
in resource-limited settings. PLoS One. 2011;6(11):e28184. [PMID
22132237]
2. Yang C, et al. Development and application of a broadly
sensitive dried-blood-spot-based genotyping assay for global
surveillance of HIV-1 drug resistance. J Clin Microbiol. 2010
Sep;48(9):3158-64. [PMID 20660209]
Intellectual Property: HHS Reference No. E-259-2013/0--
PCT Application No. PCT/US2012/045523 filed 05 Jul 2012,
which published as WO 2013/006684 on 10 Jan 2013
US Patent Application No. 14/125,564 filed 11 Dec 2013
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected]
Collaborative Research Opportunity: The Centers for Disease Control
and Prevention (CDC) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Real-time PCR Assay for Detection of
Pneumococcal DNA and Diagnosis of Pneumococcal Disease. For
collaboration opportunities, please contact Suzanne Shope at
[email protected] or 770-488-8613.
Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and
Therapeutics
Description of Technology: This Intranasal Dry Powder Inhaler
(DPI), developed with Creare, Inc., allows low-cost delivery of powder
vaccines. Nasal delivery has numerous advantages compared to
traditional injected vaccines, including: (1) Safe, needle-less
administration by minimally-trained staff or patient; (2) better
protection due to mucosal and cross-protection; and (3) decreased
biohazard waste. Further, dry powder aerosol vaccine delivery is
superior to liquid aerosol delivery in a number of ways, including: (1)
No dose reconstitution required; (2) highly thermostable and may not
need cold chain storage; (3) costs less to store and transport; (4)
improved efficacy through elimination of liquid spray nasal-dripping.
This CDC-Creare invention is unique in that it is inexpensive and
suitable for single-use applications, such as vaccination. It prevents
the dose being deposited within the lower respiratory tract, improving
safety. This delivery system has a broad range of potential
applications including, but not limited to, childhood vaccination
programs, self-administered therapeutics, and emergency biodefense.
Potential Commercial Applications:
Intranasal delivery of vaccines and therapeutics
Childhood vaccination programs, mass immunization
campaigns, or response to epidemics
Competitive Advantages:
Safe, needle-less delivery
Allows self-administration
Improved protection via intranasal immunization
Decreased biohazard waste
Dose reconstitution is not required
Highly thermostable and may not need cold chain storage
Cost-effective
Primate study with a thermostable measles vaccine expected
in the next year
Development Stage:
In vitro data available
Prototype
Inventors: Mark J. Papania, James J. Barry, Darin A. Knaus, Edward
Moynihan, Eric M. Friets, Mark C. Bagley (all of CDC)
Intellectual Property: HHS Reference No. E-258-2013/0--
US Provisional Patent Application No. 61/665,778 filed 28
Jun 2012
PCT Application No. PCT/US2013/047399 filed 24 Jun 2013,
which published as WO 2014/004400 on 03 Jan 2014
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Recombinant Pan-Lyssavirus for Use in Rabies and Broad-Lyssavirus
Vaccination
Description of Technology: CDC researchers have developed
recombinant lyssaviruses that can be used for the development of an
improved, broad-spectrum vaccine against several rabies genotypes.
Lyssaviruses are single-stranded RNA viruses that cause rabies and
rabies-like diseases in mammals. Currently, there are commercially
available vaccines that are considered to be effective against
infections from a single viral phylogroup; however, these vaccines
confer little or no protection against viruses outside of the
phylogroup. The present recombinants have glycoprotein-encoding genes
from at least two different lyssaviruses and can be used as pan-
lyssaviral vaccines to provide protection against infection by multiple
lyssavirus phylogroups.
Potential Commercial Applications:
Pan-lyssavirus vaccines
Rabies surveillance and vaccination programs
Competitive Advantages:
Broad-spectrum vaccine potential
Pan-lyssavirus vaccination tools will be particularly
beneficial in endemic and developing regions
Employs a presently commercialized vaccine backbone/
platform, making this innovation easily adaptable for industrial R&D
and subsequent large-scale production
Development Stage: Pre-clinical
Inventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin (all of
CDC)
Publication: Kuzmin IV, et al. Complete genomes of Aravan, Khujand,
Irkut and West Caucasian bat viruses, with special attention to the
polymerase gene and non-coding regions. Virus Res. 2008 Sep;136(1-
2):81-90. [PMID 18514350]
Intellectual Property: HHS Reference No. E-256-2013/0--
PCT Application No. PCT/US2011/041579 filed 23 June 2011,
which published as WO 2011/163446 on 29 Dec 2011
US Patent Application No. 13/806,622 filed 21 Dec 2012
Related Technologies: HHS Reference No. E-326-2013/0--
PCT Application No. PCT/US2006/040134 filed 13 Oct 2006,
which published as WO 2007/047459 on 26 Apr 2007
US Patent No. 7,863,041 issued 04 Jan 2011
Various international patent applications pending or
issued
[[Page 4738]]
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected].
Real-Time PCR Assay for Detection of Pneumococcal DNA and Diagnosis of
Pneumococcal Disease
Description of Technology: CDC scientists have developed a real-
time PCR assay for diagnosing pneumococcal disease using amplification
of the bacterial gene encoding pneumococcal surface adhesin A (PsaA).
Pneumococcal isolation and identification is often complicated by (1)
antimicrobial suppression of growth in culture and (2) contamination by
normal flora alpha-streptococci. Further, pneumococcal detection by
culture and serological methods can be time-consuming, relatively
expensive, laborious and, ultimately, indeterminate. Sensitive and
specific assays that can be completed quickly in the clinical
laboratory are essential for early diagnosis and effective therapy.
This RT-PCR assay provides a tool for quick and accurate diagnosis by
physicians and health care technicians and may be useful in evaluating
the efficacy of novel pneumococcal vaccines and therapeutics.
Potential Commercial Applications:
Pneumococcal disease diagnostics and surveillance programs
Streptococcus pneumoniae vaccine development and
improvement
Evaluation of efficacy of anti-pneumococcal therapeutics
Competitive Advantages:
Cost-effective
Simple to implement
Rapid, accurate and objectively conclusive
Easily implemented as a kit
Development Stage:
Pre-clinical
In vitro data available
Inventors: Jacquelyn S. Sampson, Edwin W. Ades, George Carlone,
Maria da Gloria Carvalho, Karen McCaustland (all of CDC)
Publication: Carvalho MG, et al. Evaluation and improvement of
real-time PCR assays targeting lytA, ply, and psaA genes for detection
of pneumococcal DNA. J Clin Microbiol. 2007 Aug;45(8):2460-6. [PMID
17537936]
Intellectual Property: HHS Reference No. E-250-2013/0--
PCT Application No. PCT/US2005/010449 filed 28 Mar 2005,
which published as WO 2006/104486 on 05 Oct 2006
US Patent No. 7,476,733 issued 13 Jan 2009
Various international filings issued or pending
Licensing Contact: Whitney Blair, J.D., M.P.H.; 301-435-4937;
[email protected]
Collaborative Research Opportunity: The Centers for Disease Control
and Prevention (CDC) is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate or commercialize Real-time PCR Assay for Detection of
Pneumococcal DNA and Diagnosis of Pneumococcal Disease. For
collaboration opportunities, please contact Suzanne Shope at
[email protected] or 770-488-8613.
T24 Antigen for Diagnosing or Treating Taenia solium Cysticercosis
Description of Technology: In order to develop a simple detection
assay for field use, CDC researchers cloned and sequenced the Taenia
solium T24 diagnostic protein. The T24 sequences can be used to detect
and diagnose T. solium infection or can be formulated into a
pharmaceutical composition. T. solium is a species of tapeworm.
Intestinal infection with T. solium is referred to as taeniasis. Many
taeniasis infections are asymptomatic but may be characterized by
insomnia, anorexia, abdominal pain and weight loss. Cysticercosis
infection, which can be fatal, may develop if T. solium larvae migrate
out of the intestine and form cysticerci in various body tissues. This
technology may be used to develop a diagnostic, vaccine, or therapeutic
for infection related to T. solium.
Potential Commercial Applications:
Vaccine or therapeutic for taeniasis or cysticercosis
resulting from T. solium infection
Diagnosis of T. solium infection